Headquarters: Basel, Switzerland
CEO: Dr. Luca Santarelli M.D.
USD as of Jan. 1, 2023
|Company||Market Cap (USD)|
|Novo Nordisk||$329.83 B|
|Vertex Pharmaceuticals Incorporated||$88.79 B|
|CSL Limited||$85.00 B|
|Marinomed Biotech AG||$84.73 B|
|Regeneron Pharmaceuticals, Inc.||$78.88 B|
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
VectivBio Holding AG has the following listings and related stock indices.
Stock: NASDAQ: VECT